In 2021, the United States witnessed over 1.9 million new cancer diagnoses and more than 610,000 deaths attributed to cancer, underscoring its profound impact on health. Globally, cancer remains a dominant cause of mortality, accounting for nearly one-sixth of deaths in 2020.

As the medical community continues to seek advancements in cancer treatment, integrated approaches combining traditional and innovative therapies have emerged. Among these, hyperbaric oxygen therapy (HBOT) is gaining recognition for its role in enhancing the effectiveness of standard cancer treatments such as radiation and chemotherapy. By enabling more precise dosing and stimulating tumor regression, HBOT also aims to mitigate the adverse effects associated with conventional cancer treatments.

Cancer cells are known to flourish in low-oxygen (hypoxic) conditions, making them more resilient and aggressive. Hyperbaric therapy counteracts this by saturating the body with increased levels of oxygen under pressure, thereby creating an environment less conducive for tumor growth and reducing their virulence. This approach not only targets the tumors directly but also supports overall patient recovery and well-being.